Strong launch continues as sickle cell decision moves to February
- The FDA extended the sickle cell disease decision date to February 1, 2027, to review additional safety data.
- The AQVESME launch showed excellent momentum in Q3 2026, generating $55.4 million in total revenue.
- Approximately 75 percent of AQVESME patients remained on therapy at six months, indicating stable demand.
- Agios is cutting research and development headcount by over 35 percent to target profitability by 2028.
- A February 2026 Paragraph IV patent challenge could bring generic risk earlier than expected.
A delayed regulatory path, but the base business grows
Agios is approaching its biggest test slightly later than planned. The FDA extended the review date for mitapivat in sickle cell disease by three months to February 1, 2027. The agency needs more time to review safety data related to a potential risk evaluation and mitigation strategy. An approval would unlock a much larger market than the company currently serves.
The bull case relies on a successful sickle cell launch paired with growing baseline revenue from AQVESME in thalassemia. Third-quarter 2026 numbers were very strong, with $55.4 million in total revenue and a 75 percent persistency rate at six months. Agios is also cutting research and development headcount by over 35 percent, aiming to reach non-GAAP profitability in 2028.
The bear case centers on the risk of an FDA rejection or a highly restrictive safety program for sickle cell disease. The Phase 3 sickle cell study met its hemoglobin goal but failed to show a statistically significant drop in pain crises. If the FDA demands a full confirmatory trial, the growth story stalls.
The stock also has a price question. Finn gives the company a low valuation score, suggesting the market expects perfection. The rest of 2026 is about proving AQVESME demand lasts, surviving the upcoming FDA review, and defending patents.
One core molecule funding new bets
Agios is a commercial rare disease biotech. Its current product revenue comes entirely from mitapivat, sold as PYRUKYND for adults with PK deficiency and as AQVESME for adults with alpha or beta-thalassemia in the United States.
That makes the business focused but highly concentrated. One drug drives the story, even though it is sold under two names. Growth depends on more doctors prescribing it, payors covering it, and regulators allowing mitapivat into more diseases.
The company has a massive cash cushion for its size, ending the third quarter of 2026 with $907 million in cash. Management is now restructuring the operating model, cutting staff and focusing on core rare hematology programs to stretch that cash to profitability in 2028.
What Agios is selling and testing
PYRUKYND
PYRUKYND is mitapivat for hemolytic anemia in adults with PK deficiency in the U.S., EU, and Great Britain. It is the base commercial product.
AQVESME
AQVESME is mitapivat for anemia in adults with alpha or beta-thalassemia in the U.S. It generated $55.4 million in total Q3 2026 revenue.
Mitapivat in sickle cell disease
Agios is seeking accelerated approval for sickle cell disease. The FDA set a February 1, 2027 decision date.
Cevidoplenib
An oral SYK inhibitor licensed from Oscotec for the treatment of ITP and other autoimmune indications. A Phase 3 trial is planned for 2028.
AG-236
A siRNA program for polycythemia vera. It is advancing to a Phase 3 program by year-end 2026.
Tebapivat (AG-946)
Tebapivat is a next-generation PK activator evaluated for lower-risk myelodysplastic syndrome and sickle cell disease.
AG-181
AG-181 is a PAH stabilizer for PKU. Agios is exploring out-licensing opportunities for this non-core asset.
Mostly U.S. mitapivat sales
Agios reports one operating segment. Product revenue is predominantly domestic, driven by U.S. sales of mitapivat, with early international revenue coming from the GCC region.
What could break the thesis
Sickle cell FDA rejection on February 1
High impact · Medium oddsThe FDA will decide on accelerated approval for sickle cell disease by February 1, 2027. The risk is that the agency rejects the filing because the Phase 3 study did not show a statistically significant cut in pain crises. A rejection would push out a major growth driver.
Restrictive safety program limits sickle cell adoption
High impact · Medium oddsThe FDA delayed the sickle cell review specifically to look at safety data for a risk evaluation and mitigation strategy. If the final safety program is highly restrictive, it could slow down doctor adoption and hurt revenue.
AQVESME launch fades after first demand
High impact · Medium oddsAQVESME showed strong early numbers and high persistency. However, early launches can include patients who were waiting for the drug. If new starts slow, the early spike may prove to be a temporary wave rather than a stable trend.
Patent challenge brings earlier generic risk
High impact · Medium oddsA generic sponsor filed an ANDA for mitapivat with a Paragraph IV certification in February 2026. This means the filer is challenging listed patents. Agios intends to sue for infringement, but an adverse outcome could shorten the period of branded pricing power.
In one breath
What does Agios Pharmaceuticals do?
Agios develops and sells medicines for rare blood diseases. Its main drug is mitapivat, sold as PYRUKYND for PK deficiency and AQVESME for thalassemia.
What is the biggest upcoming Agios catalyst?
The key catalyst is the February 1, 2027 FDA decision date for mitapivat in sickle cell disease. An approval would sharply expand the company's addressable market.
What is the main risk for AGIO stock?
The main risk is that the FDA rejects the sickle cell disease application due to mixed trial data. A weak AQVESME launch trend or a patent loss could also hurt the thesis.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 8, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Agios Pharmaceuticals, Inc. in Finn's Biotechnology industry ranking.

